Featured Clinical Trial:

Diffuse Large B-Cell Lymphoma (product/compound: Pixantrone; Rituximab; Gemcitabine)

ClinicAid Locations: Southern California – Fountain Valley, Corona, Riverside

Status:
Open for enrollment (accepting patients). Please contact us and mention Trial ID NCT01321541.

Condition: Diffuse Large B-cell Lymphoma

Product Name/Compound: Pixantrone + Rituximab; Gemcitabine + Rituximab

Full Study Title: A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant

Study Summary: The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Eligible Participants:

Inclusion (Eligible):

1. Men and women >= 18 years of age
2. Diagnosis of DLBCL or DLBCL transformed from follicular lymphoma
3. Received at least one and not more than 3 prior therapies for aggressive NHL
4. Received CHOP + rituximab or equivalent regimen for aggressive NHL
5. Not eligible for high-dose chemotherapy and stem cell transplant

Exclusion (Not Eligible):

1. Primary refractory aggressive NHL
2. Prior treatment with cumulative dose of doxorubicin or equivalent exceeding 450 mg/m2
3. Any experimental therapy <= 28 days prior to randomization
4. Other malignancy within last 5 years other than curatively treated basal cell/squamous cell skin cancer, carcinoma in situ of the cervix, or superficial transitional cell bladder carcinoma
5. Any contraindication or known allergy or hypersensitivity to any study drugs
6. Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies. Low-dose corticosteroids for the treatment of non cancer-related illnesses are permitted.

Study Phase: Phase III (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT01321541

<< Back to all ClinicAid clinical trials